Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Marta Seghieri, Alexander S. Christensen, Andreas Andersen, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
Simona Marchisello, Antonino Di Pino, Roberto Scicali, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1948-1948
Open Access | Times Cited: 171
NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2
Marinko Marušić, Matej Paić, Mia Knobloch, et al.
Canadian Journal of Gastroenterology and Hepatology (2021) Vol. 2021, pp. 1-9
Open Access | Times Cited: 147
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint, Grit Andersen, Paul Hockings, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 9, pp. 1150-1161
Open Access | Times Cited: 145
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 311-319
Open Access | Times Cited: 139
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 125
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 888-897
Open Access | Times Cited: 97
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Dhruv Gupta, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101979-101979
Open Access | Times Cited: 84
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 72
GLP-1a: Going beyond Traditional Use
Lucas Fornari Laurindo, Sandra Maria Barbalho, Élen Landgraf Guiguer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 739-739
Open Access | Times Cited: 71
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 65
Inter‐organ communication: a gatekeeper for metabolic health
Judit Castillo‐Armengol, Lluís Fajas, Isabel C. López‐Mejía
EMBO Reports (2019) Vol. 20, Iss. 9
Open Access | Times Cited: 134
Metabolic Targets in Nonalcoholic Fatty Liver Disease
William P. Esler, Kendra K. Bence
Cellular and Molecular Gastroenterology and Hepatology (2019) Vol. 8, Iss. 2, pp. 247-267
Open Access | Times Cited: 124
Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease
Anand Saran, Shravan Dave, Amir Zarrinpar
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1948-1966.e1
Open Access | Times Cited: 122
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, et al.
Hepatology Communications (2021) Vol. 6, Iss. 1, pp. 120-132
Open Access | Times Cited: 103
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 53
Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis
Sanjay Bandyopadhyay, Saibal Das, Shambo Samrat Samajdar, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 10, pp. 102849-102849
Closed Access | Times Cited: 33
Incretin-based investigational therapies for the treatment of MASLD/MASH
Bram Brouwers, Girish S. Rao, Yuanyuan Tang, et al.
Diabetes Research and Clinical Practice (2024) Vol. 211, pp. 111675-111675
Open Access | Times Cited: 12
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Mariam M. Ali, Sanober Parveen, Vanessa Williams, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100341-100341
Open Access | Times Cited: 9
Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non‐alcoholic fatty liver disease: A pilot randomized trial
Joan Khoo, John Hsiang, Timothy Shao Ern Tan, et al.
Diabetes Obesity and Metabolism (2017) Vol. 19, Iss. 12, pp. 1814-1817
Closed Access | Times Cited: 87
Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
Lucia Kořínková, Veronika Pražienková, Lucie Černá, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 66
Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling
Rania M. Khalil, Ahmed Shata, Eman M. Abd El-Kader, et al.
Toxicology and Applied Pharmacology (2020) Vol. 407, pp. 115246-115246
Closed Access | Times Cited: 55
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
Gianluca Svegliati‐Baroni, Bárbara G. Patrício, Gessica Lioci, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5820-5820
Open Access | Times Cited: 54
Glucagon's Metabolic Action in Health and Disease
Anja Zeigerer, Revathi Sekar, Maximilian Kleinert, et al.
Comprehensive physiology (2021), pp. 1759-1783
Open Access | Times Cited: 54
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
Baptist Gallwitz, Francesco Giorgino
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 50
Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
Han Ah Lee, Hwi Young Kim
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9324-9324
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top